Market research
336P.F Hepion Pharmaceuticals, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 6.33
- Dividend yield
- 0.0%
- Beta
- 1.63
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4268971045
- Market cap
- 35M
- P/E ratio
- Not available
- Analyst target
- 6.33
- Dividend yield
- 0.0%
- Beta
- 1.63
About
About Hepion Pharmaceuticals, Inc
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 336P.F discussion.
5 years, 5 months ago
Hepion Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 12.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Hepion Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 161.6% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 88.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Hepion Pharmaceuticals, Inc gets an overall score of 1/5.